Our findings demonstrated increased RAD51 levels correlated with worse patient outcomes clinically, and confirmed our hypothesis that increased repair capacity of DNA damage could be a mechanism of treatment resistance in GBM and possibly other cancers. This evidence concerns the gene RAD51 and cancer.